1. Home
  2. QNCX vs MDXH Comparison

QNCX vs MDXH Comparison

Compare QNCX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$2.81

Market Cap

167.0M

Sector

Health Care

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.23

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNCX
MDXH
Founded
2012
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.0M
167.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
QNCX
MDXH
Price
$2.81
$3.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$7.67
$7.67
AVG Volume (30 Days)
698.3K
120.7K
Earning Date
11-12-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$0.72
$1.35
52 Week High
$4.55
$5.33

Technical Indicators

Market Signals
Indicator
QNCX
MDXH
Relative Strength Index (RSI) 38.83 39.88
Support Level $3.18 $3.20
Resistance Level $3.38 $3.58
Average True Range (ATR) 0.27 0.20
MACD -0.17 0.02
Stochastic Oscillator 6.51 26.00

Price Performance

Historical Comparison
QNCX
MDXH

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: